Anti-TNF Therapy in Crohn’s Disease

ACG Clinical Guideline: Management of Crohn’s Disease in Adults

(2018) Gary R Lichtenstein et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Molecular mechanisms of action of anti-TNF-α agents – Comparison among therapeutic TNF-α antagonists

(2018) Hiroki Mitoma et al.   CYTOKINE

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease

(2018) Geert D’Haens et al.   GASTROENTEROLOGY

Developing a core outcome set for fistulising perianal Crohn’s disease

(2018) Kapil Sahnan et al.   GUT

American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases

(2017) Niels Vande Casteele et al.   GASTROENTEROLOGY

American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease

(2017) Joseph D. Feuerstein et al.   GASTROENTEROLOGY

Crohn's disease

(2017) Joana Torres et al.   LANCET

Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease

(2017) Benjamin L Cohen et al.   BMJ-British Medical Journal

Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease

(2017) Benjamin L Cohen et al.   BMJ-British Medical Journal

Anti-TNF-α therapies for the treatment of Crohn’s disease: the past, present and future

(2016) Marc Berns et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Biosimilar therapies in inflammatory bowel disease: should we care about patient profile?

(2016) Gionata Fiorino et al.   Expert Review of Clinical Immunology

ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update

(2016) Silvio Danese et al.   Journal of Crohns & Colitis

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management

(2016) Fernando Gomollón et al.   Journal of Crohns & Colitis

Biosimilars in IBD: from theory to practice

(2016) Silvio Danese et al.   Nature Reviews Gastroenterology & Hepatology

Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases

(2015) K. Papamichael et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed

(2015) J. P. Gisbert et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

(2015) Niels Vande Casteele et al.   GASTROENTEROLOGY

Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease

(2015) Joana Torres et al.   GASTROENTEROLOGY

The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study

(2015) Andres J Yarur et al.   GUT

Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases

(2015) Andres J. Yarur et al.   INFLAMMATORY BOWEL DISEASES

Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice

(2015) Niels Vande Casteele et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Cancers Complicating Inflammatory Bowel Disease

(2015) Laurent Beaugerie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease

(2015) Konstantinos Papamichael   WORLD JOURNAL OF GASTROENTEROLOGY

Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease

(2014) R. W. Stidham et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Safety considerations when using anti-TNFα therapy to treat Crohn’s disease

(2014) Cristiano Pagnini et al.   Expert Opinion On Drug Safety

Miscellaneous Adverse Events with Biologic Agents (Excludes Infection and Malignancy)

(2014) Joseph D. Feuerstein et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Association Between Tumor Necrosis Factor-α Antagonists and Risk of Cancer in Patients With Inflammatory Bowel Disease

(2014) Nynne Nyboe Andersen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Outcome of elective withdrawal of anti-tumour necrosis factor-α therapy in patients with Crohn's disease in established remission

(2014) A.J. Brooks et al.   Journal of Crohns & Colitis

Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease

(2014) J.F. Rahier et al.   Journal of Crohns & Colitis

Mucosal Healing Did Not Predict Sustained Clinical Remission in Patients with IBD after Discontinuation of One-Year Infliximab Therapy

(2014) Cong Dai et al.   PLoS One

Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease

(2013) C. Steenholdt et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

(2013) Niels Vande Casteele et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Adalimumab and Infliximab Are Equally Effective for Crohn's Disease in Patients Not Previously Treated With Anti–Tumor Necrosis Factor-α Agents

(2013) Christine Kestens et al.   Clinical Gastroenterology and Hepatology

Comparative Effectiveness of Infliximab and Adalimumab for Crohn's Disease

(2013) Mark T. Osterman et al.   Clinical Gastroenterology and Hepatology

Inflammatory Bowel Disease Is Associated With an Increased Risk of Melanoma: A Systematic Review and Meta-analysis

(2013) Siddharth Singh et al.   Clinical Gastroenterology and Hepatology

Anti-TNF Antibodies in Inflammatory Bowel Disease: Do We Finally Know How it Works?

(2013) Angelos Oikonomopoulos et al.   CURRENT DRUG TARGETS

Top-Down or Step-Up Treatment in Crohn's Disease?

(2013) Gerhard Rogler   DIGESTIVE DISEASES

Targeting TNF-α for the treatment of inflammatory bowel disease

(2013) Thomas Billiet et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Drug safety evaluation of certolizumab pegol

(2013) Marc Ferrante et al.   Expert Opinion On Drug Safety

American Gastroenterological Association Institute Technical Review on the Use of Thiopurines, Methotrexate, and Anti–TNF-α Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease

(2013) Themistocles Dassopoulos et al.   GASTROENTEROLOGY

Step Up Versus Early Biologic Therapy for Crohnʼs Disease in Clinical Practice

(2013) Leyla J. Ghazi et al.   INFLAMMATORY BOWEL DISEASES

Antibodies to Infliximab and Risk of Infusion Reactions in Patients With Inflammatory Bowel Disease

(2013) Sorcha O’Meara et al.   INFLAMMATORY BOWEL DISEASES

Comparative Effectiveness of Anti-TNF Agents for Crohn’s Disease in a Tertiary Referral IBD Practice

(2012) Seema A. Patil et al.   DIGESTIVE DISEASES AND SCIENCES

Risk of Melanoma and Nonmelanoma Skin Cancer Among Patients With Inflammatory Bowel Disease

(2012) Millie D. Long et al.   GASTROENTEROLOGY

Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial

(2012) Paul Rutgeerts et al.   GASTROENTEROLOGY

Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for crohnʼs perianal fistulas

(2012) Phil Tozer et al.   INFLAMMATORY BOWEL DISEASES

Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study

(2012) Casper Steenholdt et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay

(2011) N. Vande Casteele et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review

(2011) Vincent Billioud et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

(2011) Alexander C Ford et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial

(2011) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

(2011) Edouard Louis et al.   GASTROENTEROLOGY

Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

(2011) Natalie A. Molodecky et al.   GASTROENTEROLOGY

Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease

(2011) Jean-Frédéric Colombel et al.   INFLAMMATORY BOWEL DISEASES

Maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort

(2010) A. W. G. Waugh et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease - subgroup results from a placebo-controlled study

(2010) S. Schreiber et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Pregnancy and Pediatrics

(2010) Uma Mahadevan et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies

(2010) Diane R. Mould et al.   BIODRUGS

Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab

(2010) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months

(2010) Gary R. Lichtenstein et al.   Clinical Gastroenterology and Hepatology

A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease

(2010) W. Miehsler et al.   Journal of Crohns & Colitis

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Transmembrane TNF- : structure, function and interaction with anti-TNF agents

(2010) T. Horiuchi et al.   RHEUMATOLOGY

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

(2009) Javier P Gisbert et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Serum sickness, encephalitis and other complications of anti-cytokine therapy

(2009) Séverine Vermeire et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Adalimumab for the treatment of fistulas in patients with Crohn's disease

(2009) J-F Colombel et al.   GUT

Adalimumab safety in global clinical trials of patients with Crohnʼs disease

(2009) Jean-Frédéric Colombel et al.   INFLAMMATORY BOWEL DISEASES

Placental Transport of Immunoglobulins: A Clinical Review for Gastroenterologists Who Prescribe Therapeutic Monoclonal Antibodies to Women During Conception and Pregnancy

(2008) Sunanda V Kane et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials

(2008) Laurent Peyrin–Biroulet et al.   Clinical Gastroenterology and Hepatology

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

(2008) H Fidder et al.   GUT

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort

(2008) F Schnitzler et al.   GUT

Is the efficacy of successful infliximab induction therapy maintained for one year lasting without retreatment in different behavior types of Crohn's disease?

(2008) T. Molnár et al.   Journal of Crohns & Colitis

Role of cytokines in inflammatory bowel disease

(2008) Fausto Sanchez-Muñoz et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Tumor necrosis factor antagonist mechanisms of action: A comprehensive review

(2007) Daniel Tracey et al.   PHARMACOLOGY & THERAPEUTICS